bisoprolol has been researched along with Myocardial Ischemia in 35 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bisoprolol reduces the perioperative incidence of death from cardiac causes and nonfatal myocardial infarction in high-risk patients who are undergoing major vascular surgery." | 9.09 | The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. ( Baars, HF; Bax, JJ; Blankensteijn, JD; Boersma, E; Poldermans, D; Roelandt, JR; Thomson, IR; Trocino, G; van de Ven, LL; van Urk, H; Vigna, C; Yo, TI, 1999) |
| "To evaluate the effect of beta1-selective blocker bisoprolol on the QT and QTc dispersion in patients with chronic heart failure and to compare the responses to bisoprolol in patients with different etiologies." | 9.09 | Effect of bisoprolol on QT dispersion in patients with congestive heart failure--the etiology-dependent response. ( Chen, Y; Li, XP; Peng, DQ; Zhao, SP, 2001) |
| "Bisoprolol significantly reduced long-term cardiac death and myocardial infarction in high-risk patients after successful major cardiac vascular surgery." | 9.09 | Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. ( Baars, HF; Bax, JJ; Boersma, E; Paelinck, B; Poldermans, D; Roelandt, JR; Scheffer, MG; Thomson, IR; Trocino, G; van de Ven, LL; van Urk, H; Vigna, C, 2001) |
| "To evaluate the association between decrease in resting heart rate (RHR) and occurrence of composite cardiac clinical outcomes in coronary artery disease (CAD) patients after bisoprolol treatment." | 7.88 | Heart rate control is associated with reduced cardiovascular events in Asian patients with coronary artery disease treated with bisoprolol (BISO-CAD): results from a multi-national, real-world experience. ( Chen, X; Chen, Y; Fu, G; Huang, S; Kim, DS; Kim, TH; Liu, S; Ma, T; Nguyen Pham, V; Quang Truong, B; Yang, X; Yang, Y, 2018) |
| "To evaluate the efficacy and safety of a fixed-term combination of β-blocker bisoprolol and the calcium antagonist amlodipine in the outpatient treatment of patients with arterial hypertension (AH) and coronary heart disease (CHD)." | 7.80 | [Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease]. ( Chesnikova, AI; Kolomatskaia, OE; Safronenko, VA, 2014) |
| "To study effects of a selective beta1-adrenoblocker (B1AB) bisoprolol fumarate (conkor, Nikomed, Germany) on severity of pulmonary hypertension (PH), bronchial obstruction and bioelectric activity of the myocardium in patients with chronic obstructive pulmonary disease (COPD) associated with ischemic heart disease (IHD)." | 5.12 | [Efficacy of a cardioselective beta1-adrenoblocker bisoprolol in patients with chronic obstructive pulmonary disease in combination with ischemic heart disease]. ( Tsvetkova, OA; Veselovskaia, MV, 2007) |
| "The study was undertaken to evaluate the effects of long-term (6-month) therapy with the selective beta-blocker bisoprolol, the cytoprotector trimetazidine and their combination on the clinical course of disease, the morphofunctional parameters of the left ventricle (LV) and life quality in 71 patients with coronary heart disease (CHD) concurrent with functional classes (FC) III-IV chronic heart failure (CHF) (ejection fraction (EF) < 35%, as evidenced by echoCG)." | 5.11 | [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease]. ( Fedorova, TA; Il'ina, IuV; Rybakova, MK; Sotnikova, TI, 2004) |
| "Bisoprolol reduces the perioperative incidence of death from cardiac causes and nonfatal myocardial infarction in high-risk patients who are undergoing major vascular surgery." | 5.09 | The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. ( Baars, HF; Bax, JJ; Blankensteijn, JD; Boersma, E; Poldermans, D; Roelandt, JR; Thomson, IR; Trocino, G; van de Ven, LL; van Urk, H; Vigna, C; Yo, TI, 1999) |
| "To evaluate the effect of beta1-selective blocker bisoprolol on the QT and QTc dispersion in patients with chronic heart failure and to compare the responses to bisoprolol in patients with different etiologies." | 5.09 | Effect of bisoprolol on QT dispersion in patients with congestive heart failure--the etiology-dependent response. ( Chen, Y; Li, XP; Peng, DQ; Zhao, SP, 2001) |
| "Bisoprolol significantly reduced long-term cardiac death and myocardial infarction in high-risk patients after successful major cardiac vascular surgery." | 5.09 | Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. ( Baars, HF; Bax, JJ; Boersma, E; Paelinck, B; Poldermans, D; Roelandt, JR; Scheffer, MG; Thomson, IR; Trocino, G; van de Ven, LL; van Urk, H; Vigna, C, 2001) |
| "The Total Ischemic Burden Bisoprolol Study (TIBBS) was a randomized double-blind controlled study with two parallel groups; 330 patients from 30 centers in seven European countries with stable angina pectoris, a positive exercise test and more than two transient ischemic episodes during 48 h of Holter monitoring (central evaluation) were included." | 5.08 | Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. ( von Arnim, T, 1995) |
| "The effects of bisoprolol on transient myocardial ischemia have been compared with those of nifedipine in patients with coronary artery disease in end-stage renal failure maintained on haemodialysis." | 5.08 | [Effectiveness and tolerability of bisoprolol vs. nifedipine in uremic patients with ischemic cardiopathy in dialysis treatment]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Sorice, P; Tagliamonte, E, 1997) |
| "To evaluate the association between decrease in resting heart rate (RHR) and occurrence of composite cardiac clinical outcomes in coronary artery disease (CAD) patients after bisoprolol treatment." | 3.88 | Heart rate control is associated with reduced cardiovascular events in Asian patients with coronary artery disease treated with bisoprolol (BISO-CAD): results from a multi-national, real-world experience. ( Chen, X; Chen, Y; Fu, G; Huang, S; Kim, DS; Kim, TH; Liu, S; Ma, T; Nguyen Pham, V; Quang Truong, B; Yang, X; Yang, Y, 2018) |
| " We report a case of bisoprolol-induced bradycardia in an elderly patient with impaired renal function and use of cytochrome P450 inhibitors." | 3.88 | [Pharmacokinetic risk factors of beta-blockers overdose in the elderly: Case report and pharmacology approach]. ( Bernard, N; Bourguignon, L; De La Gastine, B; Dehan-Moya, MJ; Goutelle, S; Lafarge, L; Vial, T, 2018) |
| "To evaluate the efficacy and safety of a fixed-term combination of β-blocker bisoprolol and the calcium antagonist amlodipine in the outpatient treatment of patients with arterial hypertension (AH) and coronary heart disease (CHD)." | 3.80 | [Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease]. ( Chesnikova, AI; Kolomatskaia, OE; Safronenko, VA, 2014) |
| "Carvedilol, a selective alpha(1) and non-selective beta-adrenoceptor antagonist and antioxidant, has been shown to provide significant cardiac protection in animal models of myocardial ischemia." | 3.70 | Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. ( Chen, J; Christopher, TA; Gao, F; Gu, J; Lopez, BL; Lysko, P; Ma, XL; Ohlstein, EH; Ruffolo, RR; Yue, TL, 2000) |
| "The occurrence of sudden cardiac death (SCD) in patients with silent ischemia after myocardial infarction (MI) and the factors facilitating SCD are unknown." | 2.74 | Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). ( Abbate, A; Erne, P; Jamshidi, P; Kobza, R; Pfisterer, M; Schoenenberger, AW; Stuck, AE; Zuber, M, 2009) |
| "Trimetazidine was given in a dose 20 mg 3 times a day." | 2.71 | [Clinical and hemodynamic efficacy of selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease]. ( Fedorova, TA; Il'ina, IuV; Loshchits, NV; Rybakova, MK; Sotnikova, TI, 2004) |
| "Bisoprolol was well tolerated without between group difference in premature treatment withdrawals (82 on placebo, 75 on bisoprolol; NS)." | 2.67 | A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. ( , 1994) |
| "Bisoprolol is a new beta1-selective beta-blocker with a clear 24-h duration of action regarding symptoms and improvement of exercise capacity in patients with stable exercise-induced angina pectoris." | 2.38 | Safety and efficacy of beta-blockers in the treatment of stable angina pectoris. ( de Muinck, ED; Lie, KI, 1990) |
| "90 patients with chronic form of ischemic heart disease that have been involved in present study along with nitrates, antiplatelet agents and statins received bisoprolol (Group I), carvedilol (Group II) and ivabradine (Group III)." | 1.42 | [The comparative effectiveness of beta-blockers and inhibitors of if-iodium using in patients with stable angina pectoris]. ( Ilashchuk, T; Okipniak, I; Shirokova, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (28.57) | 18.2507 |
| 2000's | 13 (37.14) | 29.6817 |
| 2010's | 11 (31.43) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| AlHabeeb, W | 1 |
| Mrabeti, S | 1 |
| Abdelsalam, AAI | 1 |
| Chen, Y | 2 |
| Yang, X | 1 |
| Nguyen Pham, V | 1 |
| Huang, S | 1 |
| Fu, G | 1 |
| Chen, X | 2 |
| Quang Truong, B | 1 |
| Yang, Y | 1 |
| Liu, S | 1 |
| Ma, T | 1 |
| Kim, DS | 1 |
| Kim, TH | 1 |
| Lafarge, L | 1 |
| Bourguignon, L | 1 |
| Bernard, N | 1 |
| Vial, T | 1 |
| Dehan-Moya, MJ | 1 |
| De La Gastine, B | 1 |
| Goutelle, S | 1 |
| Gilyarevsky, SR | 1 |
| Golshmid, MV | 1 |
| Kuzmina, IM | 1 |
| Furuichi, Y | 1 |
| Sakamoto, A | 1 |
| Javed, O | 1 |
| Koo, K | 1 |
| El-Omar, O | 1 |
| Allen, S | 1 |
| Squires, A | 1 |
| El-Omar, M | 1 |
| Garganeeva, AA | 1 |
| Shabanova, MV | 1 |
| Chesnikova, AI | 1 |
| Safronenko, VA | 1 |
| Kolomatskaia, OE | 1 |
| Shirokova, S | 1 |
| Ilashchuk, T | 1 |
| Okipniak, I | 1 |
| Schoenenberger, AW | 2 |
| Kobza, R | 1 |
| Jamshidi, P | 1 |
| Zuber, M | 2 |
| Abbate, A | 1 |
| Stuck, AE | 1 |
| Pfisterer, M | 2 |
| Erne, P | 2 |
| Grigor'eva, NIu | 2 |
| Fleischmann, KE | 1 |
| Beckman, JA | 1 |
| Buller, CE | 1 |
| Calkins, H | 1 |
| Fleisher, LA | 1 |
| Freeman, WK | 1 |
| Froehlich, JB | 1 |
| Kasper, EK | 1 |
| Kersten, JR | 1 |
| Robb, JF | 1 |
| Valentine, RJ | 1 |
| Mamedov, MN | 1 |
| Monami, M | 1 |
| Filippi, L | 1 |
| Ungar, A | 1 |
| Sgrilli, F | 1 |
| Antenore, A | 1 |
| Dicembrini, I | 1 |
| Bagnoli, P | 1 |
| Marchionni, N | 1 |
| Rotella, CM | 1 |
| Mannucci, E | 1 |
| Fedorova, TA | 2 |
| Il'ina, IuV | 2 |
| Sotnikova, TI | 2 |
| Rybakova, MK | 2 |
| Loshchits, NV | 1 |
| Tsvetkova, OA | 1 |
| Veselovskaia, MV | 1 |
| Burckhardt, D | 1 |
| Kiowski, W | 1 |
| Dubach, P | 1 |
| Resink, T | 1 |
| Linnik, SA | 1 |
| Naurbieva, EN | 1 |
| Ponomareva, EP | 1 |
| von Arnim, T | 3 |
| Rayo Llerena, I | 1 |
| Marín Huerta, E | 1 |
| Cice, G | 1 |
| Di Benedetto, A | 1 |
| Tagliamonte, E | 1 |
| Ferrara, L | 1 |
| Sorice, P | 1 |
| Iacono, A | 1 |
| Weber, F | 1 |
| Schneider, H | 1 |
| Urbaszek, W | 1 |
| Poldermans, D | 2 |
| Boersma, E | 2 |
| Bax, JJ | 2 |
| Thomson, IR | 2 |
| van de Ven, LL | 2 |
| Blankensteijn, JD | 1 |
| Baars, HF | 2 |
| Yo, TI | 1 |
| Trocino, G | 2 |
| Vigna, C | 2 |
| Roelandt, JR | 2 |
| van Urk, H | 2 |
| Lee, TH | 1 |
| Litwack, RS | 1 |
| Gilligan, DM | 1 |
| DeGruttola, V | 1 |
| Gao, F | 1 |
| Chen, J | 1 |
| Lopez, BL | 1 |
| Christopher, TA | 1 |
| Gu, J | 1 |
| Lysko, P | 1 |
| Ruffolo, RR | 1 |
| Ohlstein, EH | 1 |
| Ma, XL | 1 |
| Yue, TL | 1 |
| Peng, DQ | 1 |
| Zhao, SP | 1 |
| Li, XP | 1 |
| Prichard, BN | 1 |
| Robin, JM | 1 |
| Paelinck, B | 1 |
| Scheffer, MG | 1 |
| de Muinck, ED | 1 |
| Lie, KI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure[NCT00832442] | 18,240 participants (Anticipated) | Observational | 2008-08-31 | Enrolling by invitation | |||
| Using Heart Rate Variability to Analyze the Effect of Beta Blockers on Intermediate Risk Patients Undergoing Laparoscopic Surgical Procedures[NCT01330654] | 0 participants (Actual) | Interventional | 2011-03-31 | Withdrawn (stopped due to no patients were enrolled. Study was closed prior to study start.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for bisoprolol and Myocardial Ischemia
| Article | Year |
|---|---|
Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Cardiovascular Diseases; Ethanolamines; Heart | 2022 |
[Perioperative cardiovascular evaluation and management for noncardiac surgery].
Topics: Adrenergic beta-Antagonists; Anesthesia; Atenolol; Bisoprolol; Fatty Acids, Monounsaturated; Fluvast | 2014 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
[Silent myocardial ischemia. Arguments against treatment].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Atenolol; Bisoprolol; Calcium Channe | 1996 |
Safety and efficacy of beta-blockers in the treatment of stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Bisoprolol; Blood Pressure; Heart Rate; Human | 1990 |
15 trials available for bisoprolol and Myocardial Ischemia
| Article | Year |
|---|---|
Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angioplasty, Balloon, Coronary; Antihypertensi | 2009 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
[Clinical and hemodynamic efficacy of selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Cardiac Output, Low; Drug A | 2004 |
[Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
Topics: Aged; Aged, 80 and over; Bisoprolol; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; M | 2004 |
[Efficacy of a cardioselective beta1-adrenoblocker bisoprolol in patients with chronic obstructive pulmonary disease in combination with ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Blood Gas Analysis; Female; Heart Conduction System; Humans | 2007 |
Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Bisoprolol; Death, Su | 2007 |
[Effect of the angiotensin converting enzyme inhibitor, perindopril, on heart rhythm variability and adrenoreactivity in patients with ischemic heart disease associated with duodenal ulcer].
Topics: Adrenal Glands; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Bisopr | 2007 |
Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators.
Topics: Adult; Aged; Angina Pectoris; Bisoprolol; Double-Blind Method; Electrocardiography, Ambulatory; Euro | 1995 |
A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiac Output, Low; Cardiomyopathy, Dilated; Dose-Response | 1994 |
Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Calcium Channel Blockers; Delayed-Action Preparations; Dise | 1996 |
[Effectiveness and tolerability of bisoprolol vs. nifedipine in uremic patients with ischemic cardiopathy in dialysis treatment].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Calcium Channel Blockers; Female; Humans; Male; Middle Aged | 1997 |
Heart rate variability and ischaemia in patients with coronary heart disease and stable angina pectoris; influence of drug therapy and prognostic value. TIBBS Investigators Group. Total Ischemic Burden Bisoprolol Study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Bisoprolol; Calcium Channel Blockers; Cir | 1999 |
The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Female; Heart Diseases; Heart Rate; Humans; Incidence | 1999 |
Effect of bisoprolol on QT dispersion in patients with congestive heart failure--the etiology-dependent response.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Cardiomyopathy, Dilated; Female; Heart Conduction Sys | 2001 |
Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery.
Topics: Adrenergic beta-Antagonists; Aorta, Abdominal; Bisoprolol; Dobutamine; Echocardiography; Femoral Art | 2001 |
16 other studies available for bisoprolol and Myocardial Ischemia
| Article | Year |
|---|---|
Heart rate control is associated with reduced cardiovascular events in Asian patients with coronary artery disease treated with bisoprolol (BISO-CAD): results from a multi-national, real-world experience.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Asian People; Bisoprolol; China; Coronary Artery Disea | 2018 |
[Pharmacokinetic risk factors of beta-blockers overdose in the elderly: Case report and pharmacology approach].
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Aging; Atrial Fibrillation; Bisoprolol; Bradycardia; | 2018 |
Topics: Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Drug Therapy, Combination; Humans; Hypertensio | 2018 |
Clinic and ambulatory heart rates in patients with ischaemic heart disease and/or chronic heart failure taking rate-limiting medications: are they interchangeable?
Topics: Adrenergic beta-1 Receptor Antagonists; Ambulatory Care Facilities; Bisoprolol; Chronic Disease; Ele | 2015 |
[Effect of optimal pulse slowing therapy on the course of recovery period in patients with ischemic heart disease after surgical myocardial revascularization].
Topics: Benzazepines; Bisoprolol; Cardiovascular Agents; Comparative Effectiveness Research; Drug Monitoring | 2014 |
[Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Amlodipine; Bisoprolol; Blood Pressure; Calcium Channe | 2014 |
[The comparative effectiveness of beta-blockers and inhibitors of if-iodium using in patients with stable angina pectoris].
Topics: Adrenergic beta-Antagonists; Angina, Stable; Benzazepines; Bisoprolol; Carbazoles; Carvedilol; Elect | 2015 |
[Efficacy of therapy with bisoprolol and ivabradine in patients with ischemic heart disease combined with chronic obstructive pulmonary disease assessment of parameters of 24-hour ECG monitoring].
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Bronchoconstriction; Cyclic Nucleotide- | 2009 |
2009 ACCF/AHA focused update on perioperative beta blockade.
Topics: Adrenergic beta-Antagonists; Atrioventricular Block; Bisoprolol; Evidence-Based Medicine; Heart Dise | 2009 |
[Assessment of therapeutic equivalence of original bisoprolol and its generics in patients with ischemic heart disease with concomitant chronic obstructive pulmonary disease].
Topics: Adult; Aged; Biological Availability; Bisoprolol; Comorbidity; Drug Monitoring; Drug Substitution; D | 2012 |
[Broadened indications for the use of selective β-adrenoblockers].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Calcium Channel Blockers; Female; | 2012 |
[TIBBS (Total Ischaemic Burden Bisoprolol Study)].
Topics: Bisoprolol; Electrocardiography, Ambulatory; Humans; Male; Myocardial Ischemia | 1993 |
Reducing cardiac risk in noncardiac surgery.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Heart Diseases; Humans; Incidence; Myocardial Infarction; M | 1999 |
Beta-blockade for patients undergoing vascular surgery.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Exercise Tolerance; Heart Diseases; Humans; Myocardial Isch | 2000 |
Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Bisoprolol; Carbazoles | 2000 |
Beta-blockade and surgery.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Heart Diseases; Humans; Myocardial Infarction; Myocardial I | 2001 |